We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a ...

StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note ...

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...

Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.

Investment management company Vulcan Value Partners recently released its fourth-quarter 2024 investor letter. A copy of the ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Investment analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Elevance Health in a research note ...

Elevance Health reported stronger-than-expected results and raised its dividend as it benefited from higher premiums, ...